Physician profile
Amy Jacobs
NPI 1841588605
$3,579.50
in general payments reported to CMS, 2019-2025
26 companies · $75.09 in 2025
The $75.09 reported for 2025 was less than what a typical Obstetrics & Gynecology (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $735 · 2022: $980 · 2023: $997 · 2024: $793 · 2025: $75.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,725 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.61 |
| Education | $140.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $623.12 | 2022-2024 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $501.34 | 2021-2023 | |
| Abbvie INC. | $501.26 | 2021-2023 | |
| Evofem Biosciences, INC. | $231.54 | 2021-2024 | Phexxi |
| Biogen, INC. | $229.69 | 2024 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $203.27 | 2021-2023 | |
| Pfizer INC. | $157.26 | 2021-2023 | |
| Myovant Sciences INC. | $156.78 | 2021-2022 | |
| Millicent US INC | $136.74 | 2023-2024 | Intrarosa, Femring |
| Organon LLC | $133.14 | 2021-2024 | Nexplanon |
| Shield Therapeutics INC | $117.41 | 2023-2024 | Accrufer |
| Medtronic, INC. | $117.30 | 2023-2025 | Ligasure |
| Exeltis, USA INC. | $76.72 | 2021-2024 | Tyblume |
| Merck Sharp & Dohme LLC | $68.13 | 2021-2022 | |
| Davol INC. | $57.21 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $42.30 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $42.29 | 2023 | Myfembree |
| Myriad Women'S Health, INC. | $26.10 | 2023 | Myrisk |
| Scynexis, INC. | $25.56 | 2022 | |
| Mylan Pharmaceuticals INC. | $23.84 | 2022 | |
| Therapeuticsmd, INC. | $22.07 | 2022 | |
| Hologic Sales and Service, LLC | $21.51 | 2024 | Thinprep 2000 Processor, Aptima |
| Pacira Pharmaceuticals Incorporated | $19.21 | 2021 | |
| Mission Pharmacal Company | $16.34 | 2023 | Citranatal |
| Coopersurgical, INC. | $14.72 | 2024 | Paragard T 380a |
| Sage Therapeutics, LLC | $14.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.